MaxCyte

Sarah Meeks, Ph.D., Senior Vice President, Business Development

April 13 | 1:45pm | Dark Horse Consulting Ballroom 

Rockville, MD

(NASDAQ: MXCT)

MaxCyte is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development, and commercialization. Over the past twenty years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. Our broad intellectual property (IP) portfolio, along with our regulatory certifications and support, offer our partners both enhanced IP protection and freedom to operate.

www.maxcyte.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions